{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:20:23Z","timestamp":1793733623453,"version":"4.6.1"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamaoncol.2020.5012","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T15:02:37Z","timestamp":1603983757000},"page":"1952","source":"Crossref","is-referenced-by-count":436,"title":["Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Bairavi","family":"Shankar","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, East Carolina University, Greenville, North Carolina"},{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine L.","family":"Feliciano","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Marrone","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ettinger","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Hann","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Perugia, Perugia, Italy"},{"name":"Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight","family":"Owen","sequence":"additional","affiliation":[{"name":"The Ohio State University\u2013James Comprehensive Cancer Center, the Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, East Carolina University, Greenville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[{"name":"The Ohio State University\u2013James Comprehensive Cancer Center, the Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip H.","family":"Patel","sequence":"additional","affiliation":[{"name":"The Ohio State University\u2013James Comprehensive Cancer Center, the Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland"},{"name":"Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland"},{"name":"The Royal College of Surgeons of Ireland, Beaumont Hospital Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"cbr200016r1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer.","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"cbr200016r2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer.","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"2","key":"cbr200016r3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"cbr200016r4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"cbr200016r5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"cbr200016r6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"17","key":"cbr200016r7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5S","key":"cbr200016r8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: recognition and management of immunotherapy-related toxicity.","volume":"16","author":"Thompson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"cbr200016r9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"11","key":"cbr200016r10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"cbr200016r11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"230","key":"cbr200016r12","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"30","key":"cbr200016r13","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody.","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2772169\/jamaoncology_shankar_2020_br_200016_1606943438.46844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T16:47:48Z","timestamp":1607618868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2772169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}